Cargando…

Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study

PURPOSE: Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk....

Descripción completa

Detalles Bibliográficos
Autores principales: Berge, Leon Alexander Mclaren, Andreassen, Bettina Kulle, Stenehjem, Jo Steinson, Heir, Trond, Karlstad, Øystein, Juzeniene, Asta, Ghiasvand, Reza, Larsen, Inger Kristin, Green, Adele C, Veierød, Marit Bragelien, Robsahm, Trude Eid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755337/
https://www.ncbi.nlm.nih.gov/pubmed/33376408
http://dx.doi.org/10.2147/CLEP.S269446
_version_ 1783626333191929856
author Berge, Leon Alexander Mclaren
Andreassen, Bettina Kulle
Stenehjem, Jo Steinson
Heir, Trond
Karlstad, Øystein
Juzeniene, Asta
Ghiasvand, Reza
Larsen, Inger Kristin
Green, Adele C
Veierød, Marit Bragelien
Robsahm, Trude Eid
author_facet Berge, Leon Alexander Mclaren
Andreassen, Bettina Kulle
Stenehjem, Jo Steinson
Heir, Trond
Karlstad, Øystein
Juzeniene, Asta
Ghiasvand, Reza
Larsen, Inger Kristin
Green, Adele C
Veierød, Marit Bragelien
Robsahm, Trude Eid
author_sort Berge, Leon Alexander Mclaren
collection PubMed
description PURPOSE: Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level. PATIENTS AND METHODS: In the Cancer Registry of Norway, we identified all cases aged 18–85 with a first primary cutaneous melanoma diagnosed in 2007–2015 (n=12,106). These were matched to population controls from the Norwegian National Registry 1:10 (n=118,564), on sex and year of birth using risk set sampling. Information on prescribed drugs (2004–2015) was obtained by linkage to the Norwegian Prescription Database (NorPD). Conditional logistic regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for associations between use of immunomodulating drugs (immunosuppressants and corticosteroids) and melanoma risk, adjusted for ambient UVR and other drug use. RESULTS: Compared with ≤1 prescription, use of ≥8 prescriptions of immunosuppressants was associated with increased risk of melanoma (RR 1.50, 95% CI 1.27, 1.77). Similar associations were found for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) (RR 2.02, 95% CI 1.35, 3.03) and methotrexate (RR 1.27, 95% CI 1.04, 1.55). Similar results were found for high levels of cumulative doses and across all histological subtypes. Use of corticosteroids was not associated with melanoma risk. CONCLUSION: We found a positive association between use of immunosuppressants and melanoma risk, with the highest risk seen for drugs prescribed to OTRs. Knowledge about this risk increase is important for physicians and users of these drugs, for intensified surveillance, awareness and cautious sun exposure.
format Online
Article
Text
id pubmed-7755337
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77553372020-12-28 Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study Berge, Leon Alexander Mclaren Andreassen, Bettina Kulle Stenehjem, Jo Steinson Heir, Trond Karlstad, Øystein Juzeniene, Asta Ghiasvand, Reza Larsen, Inger Kristin Green, Adele C Veierød, Marit Bragelien Robsahm, Trude Eid Clin Epidemiol Original Research PURPOSE: Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level. PATIENTS AND METHODS: In the Cancer Registry of Norway, we identified all cases aged 18–85 with a first primary cutaneous melanoma diagnosed in 2007–2015 (n=12,106). These were matched to population controls from the Norwegian National Registry 1:10 (n=118,564), on sex and year of birth using risk set sampling. Information on prescribed drugs (2004–2015) was obtained by linkage to the Norwegian Prescription Database (NorPD). Conditional logistic regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for associations between use of immunomodulating drugs (immunosuppressants and corticosteroids) and melanoma risk, adjusted for ambient UVR and other drug use. RESULTS: Compared with ≤1 prescription, use of ≥8 prescriptions of immunosuppressants was associated with increased risk of melanoma (RR 1.50, 95% CI 1.27, 1.77). Similar associations were found for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) (RR 2.02, 95% CI 1.35, 3.03) and methotrexate (RR 1.27, 95% CI 1.04, 1.55). Similar results were found for high levels of cumulative doses and across all histological subtypes. Use of corticosteroids was not associated with melanoma risk. CONCLUSION: We found a positive association between use of immunosuppressants and melanoma risk, with the highest risk seen for drugs prescribed to OTRs. Knowledge about this risk increase is important for physicians and users of these drugs, for intensified surveillance, awareness and cautious sun exposure. Dove 2020-12-18 /pmc/articles/PMC7755337/ /pubmed/33376408 http://dx.doi.org/10.2147/CLEP.S269446 Text en © 2020 Berge et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Berge, Leon Alexander Mclaren
Andreassen, Bettina Kulle
Stenehjem, Jo Steinson
Heir, Trond
Karlstad, Øystein
Juzeniene, Asta
Ghiasvand, Reza
Larsen, Inger Kristin
Green, Adele C
Veierød, Marit Bragelien
Robsahm, Trude Eid
Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study
title Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study
title_full Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study
title_fullStr Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study
title_full_unstemmed Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study
title_short Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study
title_sort use of immunomodulating drugs and risk of cutaneous melanoma: a nationwide nested case-control study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755337/
https://www.ncbi.nlm.nih.gov/pubmed/33376408
http://dx.doi.org/10.2147/CLEP.S269446
work_keys_str_mv AT bergeleonalexandermclaren useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT andreassenbettinakulle useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT stenehjemjosteinson useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT heirtrond useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT karlstadøystein useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT juzenieneasta useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT ghiasvandreza useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT larseningerkristin useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT greenadelec useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT veierødmaritbragelien useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy
AT robsahmtrudeeid useofimmunomodulatingdrugsandriskofcutaneousmelanomaanationwidenestedcasecontrolstudy